Teva’s NTE Strategy Initially Emphasizes Pain, Glaucoma, Schizophrenia
This article was originally published in The Pink Sheet Daily
Executive Summary
Teva seeks to leverage its “new therapeutic entities” strategy devised under the regime of now-departed CEO Jeremy Levin in order to bolster revenues as it maneuvers through the patent expiration of its most profitable product, Copaxone, in May 2014.